Sera Prognostics, Inc. Class A Common Stock

Oct 21, 2026

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026

Sera Prognostics announced it will release its third quarter fiscal year 2026 financial results on November 4, 2026. A conference call and webcast will follow at 5:00 p.m. Eastern Time to discuss operational highlights and financial results. The PreTRM Test, which predicts preterm birth risk, is a key focus of the company's offerings.

SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER

Sera Prognostics has appointed Scott Gleason as Chief Financial Officer, effective August 31, 2026. Gleason brings over 25 years of experience in healthcare and capital markets, previously serving in key financial roles at Neogen Corporation and OraSure Technologies. His leadership is expected to support Sera's growth and commercialization efforts, particularly for the PreTRM Test, which aims to improve outcomes for pregnant women.

Aug 12, 2026

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Sera Prognostics reported its second quarter 2026 financial results, highlighting a successful launch of a fourth partnership program and expanded Medicaid coverage in Illinois for its PreTRM test. The company achieved significant payer engagement and received recognition for its clinical data at a major conference. However, it also reported an increased net loss and rising operating expenses.

Jul 29, 2026

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026

Sera Prognostics Inc. will report its second quarter fiscal year 2026 financial results on August 12, 2026. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and operational highlights. The company aims to enhance maternal and neonatal health through innovative biomarker information.

Jul 9, 2026

SERAPhases

PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE

Sera Prognostics announced a subgroup analysis from the PRIME trial showing that PreTRM Test-guided care significantly reduces NICU admissions by 22% in first-time pregnancies. The study highlights the test's ability to improve neonatal outcomes and suggests substantial healthcare savings. This innovative approach offers early risk identification, enabling timely interventions for better maternal and neonatal health.

SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS

Sera Prognostics has appointed Mark Capone to its Board of Directors, effective July 1, 2026. Capone brings over 40 years of experience in healthcare, particularly in diagnostics and life sciences, including his role as CEO of Myriad Genetics. His expertise is expected to support Sera's growth and the adoption of its PreTRM test, which predicts preterm birth risk.

Jun 24, 2026

SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH

Sera Prognostics is collaborating with UC San Diego and Allegro MicroSystems on a $10.4 million ARPA-H grant to develop a point-of-care diagnostic test for fetal hypoxia. This initiative aims to enhance decision-making during childbirth by providing timely information from maternal blood samples. The project reflects a shift towards proactive maternal health management.

Jun 23, 2026

SERAFDA Updates

SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY

Sera Prognostics has praised Illinois for its new legislation that expands Medicaid coverage for proteomic blood testing aimed at identifying and managing preterm birth risks. This initiative is expected to enhance maternal and neonatal health outcomes by providing early risk assessment tools. The PreTRM Test, developed by Sera, is highlighted as a key component in this effort.

Jun 1, 2026

SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

Sera Prognostics announced that Jeff Elliott will step down from its Board of Directors effective June 4, 2026. Elliott, who has been with the board since March 2025, cited increasing demands on his time as the reason for his departure. The company is actively seeking new board members to ensure leadership continuity.

May 6, 2026

SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Sera Prognostics reported its financial results for Q1 2026, highlighting a focus on commercial readiness and clinician engagement. The company published significant findings from the PRIME trial, showing its PreTRM test's effectiveness in reducing preterm births. Despite a decrease in revenue and a slight increase in net loss, Sera is actively expanding its partnerships and preparing for regulatory submissions in Europe.

Apr 22, 2026

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

Sera Prognostics Inc. has announced a conference call and webcast scheduled for May 6, 2026, to discuss its first quarter fiscal year 2026 financial results. The call will include operational highlights and a press release will be issued prior to the event. The company focuses on innovative pregnancy biomarker information to enhance maternal and neonatal health.

Mar 18, 2026

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2025 FINANCIAL RESULTS

Sera Prognostics Inc. has reported its financial results for the fourth quarter and full year 2025, highlighting several significant developments. The positive outcomes from the PRIME Study on the PreTRM Test suggest a substantial impact on reducing preterm births and complications. The company has also expanded its commercial efforts and solidified its leadership team. However, despite these achievements, Sera continues to face financial losses and declining revenue in the last quarter of 2025.

Mar 4, 2026

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026

Sera Prognostics Inc. will report its fourth quarter and fiscal year 2025 financial results on March 18, 2026. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and operational highlights. The company aims to improve maternal and neonatal health through innovative pregnancy biomarker information.

Feb 17, 2026

SERA PROGNOSTICS TO PRESENT AT TD COWEN 46th ANNUAL HEALTH CARE CONFERENCE

Sera Prognostics Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. The presentation will include a fireside chat discussing the company's latest achievements. Sera Prognostics aims to enhance maternal and neonatal health through its PreTRM Test, which predicts the risk of preterm birth.

Jan 8, 2026

▲ +7%on this news

JANUARY 2026 We are redefining pregnancy care to reduce the burden of preterm birth This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than state

Sera is aiming to redefine pregnancy care by introducing the PreTRM test, a blood-based predictor of spontaneous preterm birth risk. This test is clinically validated and supported by multiple studies. The company highlights an urgent need to address the economic burden of preterm births, which have been increasing in recent years. However, the company also acknowledges the substantial risks and uncertainties involved in their forward-looking statements regarding future operations and expectations.

▲ +11.5%on this newsshared move

Jan 7, 2026

SERAPhases

Landmark Study Finds PreTRM Blood Test Reduces Earliest Preterm Births and Newborn Complications

The PRIME Study, recently published in the journal PREGNANCY, reveals that the PreTRM blood test significantly reduces preterm births and associated complications. Involving a randomized controlled trial of 5,018 women, the study demonstrated a 56% and 32% reduction in births before 32 and 35 weeks, respectively, along with a decrease in NICU admissions. The test's effectiveness lies in its ability to identify higher-risk women for preterm birth, allowing for targeted interventions. The findings highlight the potential for transforming maternal and neonatal care and improving health outcomes, especially for disadvantaged populations.

Nov 24, 2025

Sera Announces Publication Acceptance for PRIME Study The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year

Sera Prognostics, Inc. has announced that the findings of its PRIME study, one of the largest studies focused on preterm birth, have been accepted for publication in a peer-reviewed journal. Earlier this year, the study's abstract was presented at the Society for Maternal-Fetal Medicine's annual meeting. The acceptance signifies a substantial step in the company's mission to enhance maternal and neonatal health through precise pregnancy care. Sera Prognostics aims to share detailed manuscript data at upcoming medical meetings for further scholarly communication.

SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

Sera Prognostics, Inc. reported its third quarter 2025 financial results, highlighting progress in payer initiatives and a Medicaid pilot program in Nevada. The company is preparing to publish full results from its pivotal PRIME study, which may lead to improved adoption of its PreTRM Test. Despite a revenue drop compared to the previous year and a net loss of $7.8 million, Sera's leadership changes and market engagement show potential for future growth. Their efforts continue to focus on enhancing maternal and neonatal health through innovative diagnostic solutions.

Sep 5, 2025